Skip to main content
Premium Trial:

Request an Annual Quote

Sengenics to Use OGT's Protein Array Platform for Cancer Biomarker Discovery, Clinical Trials Service


Sengenics said this week that it will launch a cancer biomarker discovery and clinical trial immunoresponse monitoring service based on Oxford Gene Technology's functional protein array platform.

Sengenics, based in Kuala Lumpur, Malaysia, said that it will launch the service in the second quarter from a new protein array facility that has been custom built to run the OGT arrays.

Sengenics had already been offering protein array-based biomarker discovery services through OGT for a number of years. A company spokesperson said that Sengenics has built a new facility that is set to open in April and designed to run the protein array technology. "This will be the first facility in the world outside Oxford that is capable of running this platform," the spokesperson said.

In a statement, John Anson, executive vice president of R&D at OGT, noted that "enabling Sengenics, our strategic partner in Asia, to provide biomarker discovery services based on our proprietary protein array platform in their own facility" would help OGT better serve the Asian market.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.